A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations
A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC means lung cancer that has spread nearby or to other parts of the body or is unlikely to be controlled with current treatments. HER2 is a protein that helps cells to grow and divide. Sometimes, cancer cells have a damaged HER2 gene. This is called a mutation. This mutation can lead to an abnormal HER2 protein which may cause cancer cells to grow and divide too quickly.
The study treatment, sevabertinib, is designed to block the mutated HER2 protein and may help slow or stop the cancer from growing.
The main purpose of this study is to find out how well sevabertinib works and how safe it is, compared with standard treatment in participants with advanced NSCLC with a HER2 mutation.
The study participants will receive one of the study treatments:
Participants who switch to sevabertinib will continue this treatment until their disease gets worse again, they have side effects that are too severe, or they or their doctor decide to stop treatment.
During the study, the research team will:
Inclusion Criteria:
Exclusion Criteria:
Known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for five years since initiation of that therapy. Exception: the following cancer types are acceptable within five years if curatively treated or under surveillance:
Tumors with targetable alterations with approved available therapy, with the exception of HER2 mutation in the TKD.
Inability to discontinue treatment with chronic systemic corticosteroids. Participants who require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Replacement therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable, provided that the dose is stable for >4 weeks prior to planned start of study intervention.
Pre-existing peripheral neuropathy that is Grade ≥2 by CTCAE (v5.0).
History of severe hypersensitivity reaction to treatment with a monoclonal antibody.
Prior radiotherapy outside of the brain within 21 days before of planned start of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.
clinical-trials-contact@bayer.com18888422937
San Francisco, California 94158, United States
Fort Lauderdale, Florida 33316, United States
Chicago, Illinois 60612, United States
Chicago, Illinois 60637, United States
Worcester, Massachusetts 01655, United States
Farmington Hills, Michigan 48334, United States
Minneapolis, Minnesota 55455, United States
Portland, Oregon 97225, United States
Houston, Texas 77030, United States
TBC, Buenos Aires B1841, Argentina
Viedma, Río Negro Province R8500ACE, Argentina
Buenos Aires, C1431FWO, Argentina
Concord, New South Wales 2139, Australia
Heidelberg, Victoria 3084, Australia
Vienna, State of Salzburg 1090, Austria
Vienna, State of Salzburg 1090, Austria
Vienna, State of Vienna 1090, Austria
Leuven, Flemish Brabant 3000, Belgium
Roeselare, West Flanders 8800, Belgium
Brasília, Federal District 04538-132, Brazil
Natal, Rio Grande do Norte 59040-000, Brazil
Blumenau, Santa Catarina 89010-340, Brazil
São José do Rio Preto, São Paulo 15090-000, Brazil
São Paulo, 71635-610, Brazil
São Paulo, 90020-090, Brazil
Sofia, Sofia City Province 1404, Bulgaria
Sofia, Sofia City Province 1797, Bulgaria
Sofia, Sofia City Province 1797, Bulgaria
Toronto, Ontario M5G 2C4, Canada
Beijing, Beijing Municipality 100000, China
Beijing, Beijing Municipality 100142, China
Beijing, Beijing Municipality 100853, China
Beijing, Beijing Municipality 101149, China
Guangzhou, Guangdong 510230, China
Nanning, Guangxi 530021, China
Wuhan, Hubei 430023, China
Nanjing, Jiangsu 210008, China
Nanjing, Jiangsu 210029, China
Taizhou, Jiangsu 317000, China
Shanghai, Shanghai Municipality 200030, China
Shanghai, Shanghai Municipality 200032, China
Chengdu, Sichuan 610041, China
Hangzhou, Zhejiang 310016, China
Nový Jičín, Moravian-Silesian Region 741 01, Czechia
Ostrava - Vítkovice, Moravian-Silesian Region 703 00, Czechia
Olomouc, Olomouc Region 779 00, Czechia
Brno, South Moravian 602 00, Czechia
Zlín, Zlín 762 75, Czechia
Copenhagen, Capital Region / Region Hovedstaden 2100, Denmark
Aarhus N, Central Denmark Region / Region Midtjylland 8200, Denmark
Herning, Central Denmark Region / Region Midtjylland 7400, Denmark
Aalborg, North Denmark Region / Region Nordjylland 9000, Denmark
Odense, Region of Southern Denmark / Region Syddanmark 5000, Denmark
Turku, Southwest Finland 20520, Finland
La Tronche, Auvergne-Rhône-Alpes 38700, France
Pierre-Bénite, Auvergne-Rhône-Alpes 69310, France
Brest, Brittany Region 29200, France
Lille, Hauts-de-France 59000, France
Bordeaux, New Aquitaine 33076, France
Limoges, New Aquitaine 87000, France
Rouen, Normandy 76031, France
Montpellier, Occitanie 34091, France
Nantes, Pays de la Loire Region 44093, France
Saint-Herblain, Pays de la Loire Region 44800, France
Nice, Provence-Alpes-Côte d'Azur Region 06100, France
Créteil, Île-de-France Region 94010, France
Paris, Île-de-France Region 75248, France
Suresnes, Île-de-France Region 92150, France
Villejuif, Île-de-France Region 94800, France
Stuttgart, Baden-Wurttemberg 70376, Germany
Nuremberg, Bavaria 90419, Germany
Frankfurt am Main, Hesse 60590, Germany
Giessen, Hesse 35392, Germany
Cologne, North Rhine-Westphalia 51109, Germany
Essen, North Rhine-Westphalia 45147, Germany
Hemer, North Rhine-Westphalia 58675, Germany
Berlin, 12203, Germany
Chaïdári, Attica 12462, Greece
Athens, 11526, Greece
Athens, 11527, Greece
Athens, 11528, Greece
Athens, 12462, Greece
Larissa, 41110, Greece
Pylaia Thessaloniki, 555 35, Greece
Thessaloniki, 57010, Greece
Aviano, 33081, Italy
Bologna, 40138, Italy
Meldola, 47014, Italy
Milan, 20133, Italy
Orbassano, 10043, Italy
Palermo, 90146, Italy
Roma, 00144, Italy
Roma, 00168, Italy
Rozzano, 20089, Italy
Nagoya, Aichi-ken 460-0001, Japan
Kitaadachi, Saitama 362-0806, Japan
Bunkyo-ku, Tokyo 113-8603, Japan
Ube, Yamaguchi 755-0241, Japan
Monterrey, 64460, Mexico
Puebla City, 72530, Mexico
Nijmegen, Gelderland 6500 HB, Netherlands
Matosinhos Municipality, Porto District 4464-513, Portugal
Coimbra, 3004-561, Portugal
Lisbon, 1400-038, Portugal
Bucharest, 22328, Romania
Singapore, 168583, Singapore
Singapore, 258499, Singapore
Jinju, Gyeongsangnam-do 52727, South Korea
Yangsan, Gyeongsangnam-do 50612, South Korea
Hwasun-gun, Jeollanam-do 58128, South Korea
Chungcheongbuk-do, North Chungcheong 28644, South Korea
Jongno -Gu, Seoul 03080, South Korea
Majadahonda, Madrid 28222, Spain
Barcelona, 08028, Spain
Bilkent Çankaya, Ankara 6800, Turkey (Türkiye)
Kadıköy, Istanbul 34722, Turkey (Türkiye)
Sakarya, 54100, Turkey (Türkiye)
Kropyvnytskyi, 25006, Ukraine
Kyiv, 03115, Ukraine
Lutsk, 43018, Ukraine
Rivne, 33010, Ukraine
Uzhhorod, 88000, Ukraine